These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7828 related articles for article (PubMed ID: 12068386)

  • 21. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
    Brune M; Hellstrand K
    Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histamine in cancer immunotherapy.
    Hellstrand K; Hermodsson S; Brune M; Naredi P; Carneskog J; Mellqvist UH
    Scand J Clin Lab Invest; 1997 May; 57(3):193-202. PubMed ID: 9238754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
    Hellstrand K; Brune M; Dahlgren C; Hansson M; Hermodsson S; Lindnér P; Mellqvist UH; Naredi P
    Med Oncol; 2000 Nov; 17(4):258-69. PubMed ID: 11114704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histamine and interleukin-2 in acute myelogenous leukemia.
    Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
    Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
    Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH
    Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
    Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
    Front Immunol; 2018; 9():977. PubMed ID: 29780393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
    Yang LP; Perry CM
    Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
    Khayat D; Coeffic D
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells.
    Kozar K; Kaminski R; Giermasz A; Basak G; Zagozdzon R; Rybczynska J; Wasik M; Lasek W; Jakobisiak M; Golab J
    Oncol Rep; 2002; 9(2):427-31. PubMed ID: 11836621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
    Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
    J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy: the interferon-alpha experience.
    Kirkwood J
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):18-26. PubMed ID: 12068384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation.
    Johansson S; Landström M; Henriksson R
    Anticancer Res; 1999; 19(3A):1961-9. PubMed ID: 10470141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
    Brune M; Romero AI; Hellstrand K
    Inflamm Res; 2009 Apr; 58 Suppl 1():4-8. PubMed ID: 19271134
    [No Abstract]   [Full Text] [Related]  

  • 36. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
    Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
    J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of metastatic melanoma with chemotherapy and biologics.
    Atkins MB
    Curr Opin Oncol; 1997 Mar; 9(2):205-13. PubMed ID: 9161801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
    Yang LP; Perry CM
    Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
    Buzaid AC; Grimm EA; Ali-Osman F; Ring S; Eton O; Papadopoulos NE; Bedikian A; Plager C; Legha SS; Benjamin R
    Melanoma Res; 1994 Oct; 4(5):327-30. PubMed ID: 7858418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 392.